Weekly Highlights: Leadership Changes at Takeda and Johnson & Johnson; Merck's Breakthrough Drug Approved
Johnson & Johnson
Medical Device R&D and Manufacturer
"Weekly Highlights"
"Weekly Highlights" is a column launched by Siqi Club to summarize the major events in the pharmaceutical industry each week, covering the latest policy updates, news, pharmaceutical finance, drug approval progress and other industry-related content.
Personnel Changes
HUMAN RESOURCES
Edward Life Sciences Appoints Senior Vice President for Greater China
According to "Device Workplace" news, Edwards Lifesciences announced that Benjamin Cheong (钟顺和) will serve as the Senior Vice President of Greater China. He will officially join Edwards Lifesciences on April 8.
Takeda China Appoints New Head of Business Unit
According to "Pharmaceutical Academic Plus" on March 23, Takeda China appointed Liu Yan, the former head of the Hemophilia and Rare Diseases Division, as the head of Takeda China's Gastroenterology Division. This appointment will take effect from March 31.
Johnson & Johnson Medical Technologies Appoints New Executive
According to "Device Workplace" news, on March 27, Johnson & Johnson Medical Technologies announced that Tulio Oliveira will serve as the General Manager of the China Surgical Division. He will report directly to Will Song (Song Weiqun), Global Senior Vice President of Johnson & Johnson and Chairman of Johnson & Johnson China.
Policy Brief
POLICY
NHSA Issues Document, Outpatient Coordination Faces "Strongest Supervision"
On March 26, Jiangxi Province issued the "Notice on Standardizing the Management of Outpatient Coordinations for Designated Retail Pharmacies." The three most noteworthy points are basically covered in the first section, involving: offline display arrangements for medical insurance drugs, pricing of medical insurance drugs, and the intensity of supervision.
Pharmaceutical News Updates
PHARMA
Merck's Heavyweight New Drug Approved
On March 26, Merck announced that the FDA had approved the marketing application for Sotatercept for the treatment of pulmonary arterial hypertension (PAH), with the trade name Winrevair.
The Latest Purchase Price of China-Produced Bivalent HPV Vaccine Falls Below 100 Yuan
Recently, Jiangsu Government Procurement Network announced a winning bid for the bivalent HPV vaccine. In this procurement, Wantai Bio successfully won the bid. The procured product is the bivalent human papillomavirus vaccine (E. coli), also known as the bivalent HPV vaccine. The procurement quantity is 499,200 doses, at a unit price of 86 yuan per dose, with a total transaction amount of approximately 42.93 million yuan.
Breaking the Record for the Most Expensive Drug! Gene Therapy Lenmeldy Priced at $4.25 Million
On March 20, Orchard Therapeutics' official website announced the details of the commercial launch in the U.S. of the newly approved one-time gene therapy Lenmeldy (atidarsagene autotemcel), priced at $4.25 million, for the treatment of metachromatic leukodystrophy (MLD).
Pharmaceutical Finance
BUSINESS
Dong'e Ejiao Announces the Most Lavish Dividend in History
On March 22, Dong'e Ejiao disclosed its 2023 earnings report. The data shows that during the period, Dong'e Ejiao achieved a revenue of 4.715 billion yuan and a net profit attributable to shareholders of 1.151 billion yuan.
It is reported that Dong'e Ejiao announced a generous dividend plan, proposing to distribute a cash dividend of 17.80 yuan (including tax) for every 10 shares. The total cash dividend amounts to 1.146 billion yuan, which is almost equivalent to the net profit attributable to shareholders in 2023, setting a record high for the dividend payout ratio.
Nuvation Bio to Acquire Baoyuan Pharmaceuticals in All-Stock Transaction
On March 25, Nuvation Bio acquired AnHeart Therapeutics (Baoyuan Medicine) in an all-stock transaction. After the acquisition, shareholders of Baoyuan Medicine will hold 33% of the shares, while the original shareholders of Nuvation Bio will own 67%.
160% Premium! Multinational Pharmaceutical Company Acquires an AI Drug Development Firm for the First Time
AbbVie Announces Acquisition of AI Pharmaceutical Company Landos Biopharma for $212.5 Million. Based on Landos' closing price of $7.83 last Friday, the premium for this acquisition reached 160%.
ClickRead the Original Text Learn More